A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis
- PMID: 17762452
- DOI: 10.1097/RHU.0b013e318124a483
A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis
Abstract
Background: Double-filtration plasmapheresis with a plasma fractionator pore size of 20 nm should selectively remove large molecular weight substances like rheumatoid factor and IgM. This was proposed to be more likely to be helpful for rheumatoid arthritis than standard plasma exchange.
Objective: To evaluate the efficacy of double-filtration plasmapheresis (DFPP) in the treatment of patients with active rheumatoid arthritis.
Methods: Eighty-two patients were randomly assigned, 42 to the DFPP group and 40 to the no-DFPP group. All patients received sulfasalazine (0.75 g 3 times daily) plus methotrexate (10 mg orally once weekly). All patients had been on stable doses for more than 3 months. DFPP was performed once a week for 2 to 3 sessions. A total of 121 plasmapheresis procedures were performed in 42 patients. Control patients did not receive sham DFPP. The efficacy measures recorded 1 day after the final treatment and every month in follow-up for 4 to 22 months included the American College of Rheumatology (ACR) 20%, 50%, and 70% improvement criteria (ACR20, ACR50, and ACR70), the Health Assessment Questionnaire estimate of disability and the disease activity index.
Results: Patients in the DFPP group had ACR20, ACR 50, and ACR70 improvements immediately after the last treatment of 100%, 92.9%, and 81.0%, when compared with the patients in no-DFPP group 17.5%, 0%, and 0% (P < 0.001). Significant change from baseline was observed in Health Assessment Questionnaire scores in the DFPP group, but not in the no-DFPP group (P < 0.001). The changes from baseline in the disease activity scores were significantly greater than in the no-DFPP group (P < 0.001). Improvements were maintained during follow-up of 7 to 22 months.
Conclusion: This open trial showed that DFPP therapy significantly altered the signs and symptoms of active rheumatoid arthritis. There were increases in physical function and improvement in quality of life. This is proposed as an approach that merits further investigation.
Similar articles
-
Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis.J Rheumatol. 2012 Jun;39(6):1171-8. doi: 10.3899/jrheum.110978. Epub 2012 Apr 15. J Rheumatol. 2012. PMID: 22505700 Clinical Trial.
-
Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.Arthritis Rheum. 2009 Feb;60(2):335-44. doi: 10.1002/art.24266. Arthritis Rheum. 2009. PMID: 19180516 Clinical Trial.
-
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.Clin Ther. 2009 Aug;31(8):1754-64. doi: 10.1016/j.clinthera.2009.08.014. Clin Ther. 2009. PMID: 19808134 Clinical Trial.
-
Generic quality-of-life assessment in rheumatoid arthritis.Am J Manag Care. 2007 Dec;13 Suppl 9:S224-36. Am J Manag Care. 2007. PMID: 18095786 Review.
-
[Plasmapheresis for patients with RA].Nihon Rinsho. 1992 Mar;50(3):543-6. Nihon Rinsho. 1992. PMID: 1588745 Review. Japanese.
Cited by
-
Therapeutic Plasma exchange therapy in Burns.J Cutan Aesthet Surg. 2023 Jul-Sep;16(3):259-261. doi: 10.4103/JCAS.JCAS_173_21. J Cutan Aesthet Surg. 2023. PMID: 38189078 Free PMC article.
-
Efficacy and safety of dual filtration plasmapheresis combined with biological agents in active refractory rheumatod arthritis: A retrospective cohort study.Medicine (Baltimore). 2020 Jul 10;99(28):e20966. doi: 10.1097/MD.0000000000020966. Medicine (Baltimore). 2020. PMID: 32664100 Free PMC article.
-
Changes in Water Properties in Human Tissue after Double Filtration Plasmapheresis-A Case Study.Molecules. 2022 Jun 20;27(12):3947. doi: 10.3390/molecules27123947. Molecules. 2022. PMID: 35745071 Free PMC article.
-
Therapeutic apheresis in autoimmune diseases.Open Access Rheumatol. 2013 Nov 13;5:93-103. doi: 10.2147/OARRR.S34616. eCollection 2013. Open Access Rheumatol. 2013. PMID: 27790028 Free PMC article. Review.
-
MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial.Clin Rheumatol. 2018 Apr;37(4):917-925. doi: 10.1007/s10067-017-3956-3. Epub 2018 Jan 8. Clin Rheumatol. 2018. PMID: 29313271 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical